Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, is simplifying the design, fitting and care of full-face masks for sleep apnea patients. With its unique modular design, the new Amara full-face mask further demonstrates Philips’ commitment to developing solutions aimed at improving care and outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57117-philips-respironics-revolutionary-full-face-mask-sleep-therapy
The website www.MyPerfectDish.eu aims to help people with Parkinson’s, their relatives and caregivers in taking care of their nutritional requirements in order to help them enjoy tasty food that meets their dietary needs.
The website is endorsed by the European Parkinson’s Disease Association (EPDA) and sponsored by Zambon, and has been designed as an easy-to-use scientific information tool so people living with Parkinson’s can be confident that what they are reading is reliable.
“As the only European Parkinson’s umbrella organisation, the EPDA is very proud to endorse this project, which is based on solid scientific and medical grounds,” explains EPDA president Knut-Johan Onarheim. “A balanced and varied diet is important for everyone but it is even more important for people living with Parkinson’s disease because the right food intake can improve their quality of life as well as the effects of therapeutic treatments”.
“Zambon is very proud of having supported this project, which will help people with Parkinson’s and all those involved in the management of the disease. We are strongly committed to drive research and develop solutions to help patients in all their needs“. states Elena Zambon, President of Zambon.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7864251-parkinsons-diet-online-resource/
Under the leadership of the National Organization for Rare Disorders (NORD), the primary organization in the U.S. representing people with rare diseases, millions of Americans will gather tomorrow to observe the 5th annual Rare Disease Day. This international observance unites people around the globe to focus attention on the estimated 300 to 350 million patients worldwide afflicted with rare diseases and to recognize that their needs are a global public health concern. In the U.S., a rare disease is one that affects fewer than 200,000 Americans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60507-nord-rare-disease-day
A short Clip from: BBC's Horizon Special Psychedelic Experience
One would not expect Britain's traditionally conservative and oft-staid BBC to screen a 50 minute film on the new wave of psychedelic research in humans. Yet, astonishingly enough, such a state of affairs recently came to pass. Before it aired on February 27th, 1997, Psychedelic Science was heavily featured in the media, even getting elaborate treatment in the Radio Times, a mass publication as institutionalised as the BBC itself. The Times, the Guardian, and the Independent, Britain's three leading broadsheets, all carried major pieces announcing the film.
Dr. Deborah Mash and her research with ibogaine was also treated in depth in the film. Mash explains how ibogaine can be used to break cocaine habits although, as with ayahuasca, we do not not learn much about the actual phenomenology induced by ibogaine - suffice it to say that patients experience transformative insights into themselves which can break their patterns of addiction.
Some addicts may have a long history of ADHD
btw
The history of ADHD
http://adhd-npf.com/english-adhd-history-1798-alexander/
is not so new... and many addicts seems to have some of it...
http://adhd-npf.com/history-of-adhd-1902-sir-george/
Over 80% of Americans want to spend their last days at home, with friends and family. Yet, despite these desires, 75% of Americans will spend their last days in a hospital room. Many people will spend hours each day getting painful and often useless treatments and tests, and be asked to take dozens of debilitating drugs. For many, the cure is worse than the disease. This often has negative and lasting effects on family and friends who are often left with feelings of guilt and regret for years to come.
Hospice Support Fund is a 501(c)(3) non-profit organization dedicated to promoting end of life care at home rather than in a hospital so patients can spend their last days in dignity and peace, pain-free in familiar, comfortable surroundings with friends and family.
To view the multimedia release go to:
http://www.multivu.com/players/English/7785451-hospice-support-fund-end-of-life-care-psa/
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Africa and Arab States
Prof. Khalid Mohammed AlGhamdi from Saudi Arabia
Charity Society known as Faal to empower and support vitiligo patients in Saudi Arabia
Vitiligo is a long-term skin condition that causes pale, white patches on the skin due to a lack of melanin. This project aimed to increase awareness via TV broadcasts, schools visits and to provide psychological and social support to patients with vitiligo through training courses and different education programs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
